Acetazolamide for Cystoid Macular Oedema in Bietti Crystalline Retinal Dystrophy

Geoffrey K Broadhead1,3, Andrew A Chang1,3

1Sydney Institute of Vision Science, Sydney, Australia
2Sydney Retina Clinic & Day Surgery, Sydney, Australia
3Save Sight Institute, The University of Sydney, Sydney, Australia

Bietti crystalline retinal dystrophy is a rare, inherited disorder whose hallmark is the presence of retinal crystal deposits associated with later chorioretinal degeneration. This condition may rarely be complicated by the development of cystoid macular oedema leading to rapid visual decline. Currently, treatment options for this complication of Bietti dystrophy are limited and the visual prognosis is poor. Here, we present a case of cystoid macular oedema associated with Bietti dystrophy that was successfully diagnosed using multimodal imaging techniques including optical coherence tomography and fluorescein angiography. These modalities confirmed the diagnosis of macular oedema and excluded other possible causes of oedema such as choroidal neovascularisation. In this patient, cystoid macular oedema was resolved with oral acetazolamide therapy, a treatment that has not been previously reported in this context. Acetazolamide treatment resulted in oedema resolution and improvement in visual function, and can be considered a therapeutic option for other patients with Bietti dystrophy who develop cystoid macular oedema.

Key Words: Acetazolamide, Bietti crystalline dystrophy, Macular edema, Optical coherence tomography

Received: October 17, 2013 Accepted: February 5, 2014

Corresponding Author: Andrew A Chang, PhD. Sydney Retina Clinic & Day Surgery, Level 13, Park House, 187 Macquarie Street, Sydney, 2000, NSW, Australia. Tel: 61-2-9221-3755, Fax: 61-2-9221-1637, E-mail: achang@sydneyretina.com.au

© 2014 The Korean Ophthalmological Society
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
inal dystrophy presented with acute bilateral central visual impairment. Upon examination, best-corrected visual acuity (BCVA) was 6 / 60 in the right eye and 6 / 45 in the left eye. At an examination one year previously, BCVA had been 6 / 7.5 in the right eye and 6 / 18 in the left.

Dilated retinal examination revealed the presence of peripheral corneal and retina crystalline changes characteristic of Bietti dystrophy (Fig. 1A and 1B). Fluorescein angiography showed patchy hypo-fluorescence indicative of chorioretinal atrophy. No evidence of late leakage was observed, excluding the diagnosis of choroidal neovascularisation (Fig. 1C-1F). Time-domain (TD)-OCT was performed and demonstrated bilateral cystic macular lesions (Fig. 1G and 1H) with a central foveal thickness (CFT) of 242 μm in the right eye and 253 μm in the left.

On the basis of the OCT findings, the patient was diagnosed with cystoid macular oedema. Acetazolamide therapy at a dose of 500 mg daily was initiated, and one month later, visual acuity improved to 6 / 18 bilaterally and CFT reduced to 221 μm in the right eye and 225 μm in the left eye. Following one year of acetazolamide therapy, BCVA was 6 / 15 in the right eye and 6 / 24 in the left eye, and CFT had stabilised at 221 μm in the right eye and 219 μm in the left eye (Fig. 1I and 1J).

**Discussion**

Bietti crystalline retinal dystrophy is an uncommon, inherited, retinal degeneration associated with retinal crystal
deposits and progressive visual decline. Cystoid macular oedema is a rare complication of this disease, and may be associated with an acceleration of visual loss [5]. The pathogenesis of the oedema in this disorder is not well understood, and therefore treatment options are limited.

Macular oedema has been documented in association with other inherited retinal dystrophies, notably retinitis pigmentosa [6]. In this setting, it is considered that the oedema may relate to impaired RPE function, resulting in a failure of the RPE pumping mechanism [7]. Inhibition of carbonic anhydrase with acetazolamide has previously been shown to result in increased retinal pump activity [7], and has been used in this regard to treat cystoid macular oedema associated with retinitis pigmentosa [6], X-linked retinoschisis [8] and enhanced S-cone syndrome [9] with some success.

To our knowledge, this is the first case of cystoid macular oedema associated with Bietti dystrophy that was successfully treated with acetazolamide therapy in the literature. Given the reversible nature of this complication, it is important that potential treatments be recognised to preserve optimal vision.

Patients with Bietti dystrophy who develop worsening central vision should be promptly assessed to diagnose cystoid macular oedema. This complication is responsive to therapy with acetazolamide, resulting in improved anatomic outcomes and preservation of visual function.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

References

1. Wilson DJ, Weleber RG, Klein ML, et al. Bietti’s crystalline dystrophy. A clinicopathologic correlative study. Arch Ophthalmol 1989;107:213-21.
2. Rossi S, Testa F, Li A, et al. Clinical and genetic features in Italian Bietti crystalline dystrophy patients. Br J Ophthalmol 2013;97:174-9.
3. Atmaca LS, Muftuoglu O, Atmaca-Sonmez P. Peripapillary choroidal neovascularization in Bietti crystalline retinopathy. Eye (Lond) 2007;21:839-42.
4. Li A, Jiao X, Munier FL, et al. Bietti crystalline corneoretinal dystrophy is caused by mutations in the novel gene CY-P4V2. Am J Hum Genet 2004;74:817-26.
5. Parravano M, Sciamanna M, Giorno P, et al. Bietti crystalline dystrophy: a morpho-functional evaluation. Doc Ophthalmol 2012;124:73-7.
6. Fishman GA, Gilbert LD, Fiscella RG, et al. Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa. Arch Ophthalmol 1989;107:1445-52.
7. Wolfensberger TJ, Chiang RK, Takeuchi A, Marmor MF. Inhibition of membrane-bound carbonic anhydrase enhances subretinal fluid absorption and retinal adhesiveness. Graefes Arch Clin Exp Ophthalmol 2000;238:76-80.
8. Ghajarnia M, Gorin MB. Acetazolamide in the treatment of X-linked retinoschisis maculopathy. Arch Ophthalmol 2007;125:571-3.
9. Iannaccone A, Fung KH, Eyestone ME, Stone EM. Treatment of adult-onset acute macular retinoschisis in enhanced s-cone syndrome with oral acetazolamide. Am J Ophthalmol 2009;147:307-12.